Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: recombinant human protein therapeutics - Sinobiomed

Drug Profile

Research programme: recombinant human protein therapeutics - Sinobiomed

Latest Information Update: 26 Jan 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sinobiomed
  • Class Recombinant proteins
  • Mechanism of Action Hepatocyte growth factor stimulants; Kallikrein 1 stimulants; Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Liver disorders; Pancreatitis; Peripheral vascular disorders; Stroke; Thrombosis

Most Recent Events

  • 21 Aug 2008 Preclinical trials in Liver disorders in China (Parenteral)
  • 21 Aug 2008 Preclinical trials in Pancreatitis in China (Parenteral)
  • 21 Aug 2008 Preclinical trials in Peripheral vascular disorders in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top